Needleless Injection and Transcutaneous Drug Delivery Techniques Driving Novel Therapeutics in the Effort to Better Fight Disease

CHERRY HILL, N.J. -- Drug delivery, pharmaceutical

and biotech companies from around the world are aggressively competing to

bring to market new ways to introduce a variety of drugs through the dermis

without the traditional skin-breaking techniques associated with the

"traditional" needle, reports Strategic Research Institute.


Needleless injection, "pen" injection, transcutaneous "blasting" and

other commercial technologies have come a long way in delivering medicines and

are the current rage at the Ninth International Drug Delivery Technologies &

Deal-Making Summit taking place Sept. 27-29 in Cherry Hill, NJ.


The ninth annual meeting will present many new companies on the leading

edge of transdermal and transcutaneous delivery systems unveiling new

products in an ample range of therapeutic indications. These include Altea,

Shire, Eurand, 3M, Antares, Bioject, Eli Lilly, Aventis, Becton-Dickinson,

Aradigm, Felton, Nobex, and BioValve Technologies.


In addition to the needleless transdermal section of the agenda, the

newly expanded agenda features nearly 75 expert speakers on a variety of

commercial delivery applications, many of which are in clinic or beyond.  The

three-day annual information and networking extravaganza has generated a

worldwide buzz.  The meeting is geared around commercial talks from the

pharma, biotech, and drug delivery companies in search of partners and the

financial community in search of investments.


The industry is actively interested in many routes of insulin delivery and

delivery vehicles for other disease states as well as diabetes. Partnering

opportunities abound in inflammation, asthma, cancer delivery, anti-infective,

dermotologic, and cardiovascular indications.   In addition to the conference

sessions, networking functions studded throughout the 2004 gathering foster

new relationships among the pharmaceutical and delivery companies.


Source: Strategic Research Institute